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Gene Ontology (GO) provides a controlled vocabulary, which is used by several 
groups around the world to provide functional annotation to proteins across a 
wide range of species (www.geneontology.org).  The Cardiovascular Gene 
Ontology Annotation Initiative is funded the British Heath Foundation to supply 
GO annotation specifically for human proteins involved in cardiovascular (CV) 
processes.  This is the first time that a physiological process-centred approach 
has been used for human protein GO annotation1.  Experienced GO curators 
from the BHF-UCL team work alongside the bench scientists from the CV 
genetics group at University College London (UCL). By working in a CV 
dedicated environment the GO curators are developing their expertise in this 
field; this is leading to more detailed and accurate GO annotation of CV-
relevant genes.  Since the start of the project in November 2007 we have 
added over 4700 annotations to 649 human CV related proteins, as shown in 
figure 1.
Identification of CV related genes and proteins
Over 4000 CV-related genes were identified by combining:
•  the ITMAT consortium list of approximately 2,200 genes2
•  a list of 282 congenital heart disease candidate genes3
•  a list of approximately 2,500 genes identified by the BHF-UCL team as 
associated with CV-relevant GO terms at the start of the project
•  170 genes provided by our advisory board
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Figure 1a - BHF-UCL Annotation Progress, Proteins
Figure 1b - BHF-UCL Annotation Progress, Annotations
Figure 2 – How the GO was developed to reflect published knowledge on 
lipoprotein particle biology. 
Key
Unshaded terms existed prior to 
the start of this project.
Shaded terms created on request 
of the BHF-UCL team.
Process-centric annotation method
We followed a gene by gene annotation approach for the first year of the 
project.  However, whilst reading the literature for a single gene, we often 
annotated several other genes within the same pathway as they would be 
discussed within the same papers.  Thus for the second year we decided to 
trial a process-centric approach.
The benefit of annotating in this process-centric manner is a deeper 
understanding of the CV-related pathways by the BHF-UCL team.  This 
increased understanding generally results in: 
•  increased granularity of GO annotation
•  greater consistency of GO annotations across each process
•  improved input to ontology development
For example, during the annotation of the process lipoprotein particle 
clearance, the CV genetics group at UCL provided considerable advice on 
the appropriate GO terms to use for each of the human apolipoproteins, 
identified relevant publications for the BHF-UCL team to annotate, and 
contributed to the development of the lipoprotein particle cellular 
component ontology as shown in figure 2.
Ontology Development
The GO editorial office develops and refines the GO in small, medium and large scale 
projects4.  The close association of the BHF-UCL annotation team in an active bench 
science CV research laboratory and the intensive reading required as part of the 
annotation process, means that the BHF-UCL team has gained considerable expertise 
in various aspects of CV system, processes and development.  Therefore the BHF-
UCL team is able to successfully instigate both small and medium scale GO 
development projects in CV related areas with the GO editorial office.
Figure 2 shows one example of an ontology development project that was undertaken 
by the BHF-UCL team. New terms were developed in consultation with lipoprotein 
researchers based at the UCL CV genetics laboratory.
Conclusions
•  A gene-by-gene annotation process promotes the 
complete annotation of a single gene.
•  A process-centric approach allows the annotator to gain a 
deeper understanding of a specific pathway, and promotes 
the annotation of all the genes involved within that pathway.
•  A major benefit of undertaking GO annotation in a process-
centric approach is the development and refinement of the 
ontology, which occurs alongside the annotation process. 
Contact us: Email: GOannotation@UCL.ac.uk
Wiki: wiki.geneontology.org/index.php/Cardiovascular
Website: www.cardiovasculargeneontology/feedback 
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